Top Oral Biologics Drugs Companies Advancing AI-Driven Drug Delivery and Next-Generation Therapies

The global oral biologics drugs landscape is evolving with the usage of machine learning and artificial intelligence for refining and advancing drug design. The technologies can be customized for enhancing analytics power and predictive accuracy, opening doors to new avenues for product development. A recent instance of tech-deployment is the partnership between Novo Nordisk and Vivtex, which the companies announced in February 2026. This deal is aimed at developing next-gen oral biologic medicines that target diabetes, obesity, and related conditions. Such developments are likely to pave way to a new era for the biologics sector over the forthcoming years.

Developed to be consumed orally, oral biologics are derived from biological sources such as genes and proteins. Some of the examples comprise tissues for transplantation, insulin therapy for diabetes, and immunotherapy treatments for cancer. According to Fortune Business Insights, the global market for oral biologics drugs is likely to hit USD 54.80 billion by 2034 from USD 10.70 billion in 2026, depicting a CAGR of 22.65% over 2026 to 2034.

10 Dominant Oral Biologics Players: A Brief Account

To gain a strong standing, eminent participants in this sector are enhancing their investments and joining forces with companies that align with their growth plans. They are also adding new products to their lineup by pressing R&D activities to enhance their share in the global market.

The top 10 oral biologics drugs players and the prime endeavors that they are undertaking for strengthening their industry footprint have been discussed below:

1. Novo Nordisk A/S

Novo Nordisk, with its base in Denmark, extensively conducts research activities for developing innovative oral drug delivery solutions. With a portfolio that spans medications for a wide array of serious chronic illnesses, the company is keen to make investments toward developing new products to strengthen its capabilities. This is evident from its USD 2.1 billion agreement with Vivtex in February 2026 for enhancing its metabolic portfolio with next-gen delivery mechanisms.

2. Chiesi Farmaceutici S.p.A.

With a workforce of more than 7500 employees, Italy-based Chiesi Farmaceutici offers advanced therapeutic solutions in the areas of rare diseases, respiratory health, and specialty care. In 2024, the company’s revenues touched EUR 3.4 billion (~USD 2.93 billion), as per data from its website. The oral biologics drugs company’s ambitious plans can be reflected in its June 2025 announcement when it expressed intent for acquisitions to enhance its sales to USD 6.9 billion by 2030.

3. Eli Lilly and Company

Eli Lilly and Company, headquartered in the U.S., has a rich research-backed portfolio spanning cancer, migraine, autoimmune diseases, and dermatology, among others. The company is keen to develop advanced products and introduce them for ensuring enhanced care. This fervor can be witnessed in the company’s March 2026 announcement for rolling out orforglipron, its new oral obesity drug, in the U.S. Following approval from the FDA, the product would debut the market in the second quarter of 2026.

4. Rani Therapeutics Holdings, Inc.

Rani Therapeutics is dedicated to enhancing patient care by replacing injections with pills aimed at minimal gastrointestinal discomfort. With headquarters located in the U.S., the oral biologics drugs company has developed a robotic pill called the RaniPill® Capsule aimed at biologics delivery through the oral route. In January 2026, the company began Phase 1 clinical trial for assessing RT-114’s tolerability, safety, pharmacokinetics, bioavailability, and pharmacodynamics of single and multiple doses.

5. Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals, since its inception in 2006, develops enhanced solutions for oral drug delivery. The company’s flagship product is its oral insulin capsule for treating type 2 diabetes and is currently in clinical trials under the U.S. FDA. In February 2025, the Israel-based oral biologics drugs organization struck a definitive agreement with Hefei Tianhui Biotech Co., Ltd., for the formation of a joint venture, OraTech Pharmaceuticals Inc, a spin-off of Oramed’s POD technology.

6. Entera Bio Ltd.

With headquarters situated in Israel, Entera Bio has created its mark as a developer of first-in-class oral therapies. Some of the major areas of application comprise HypoPT, osteoporosis, metabolic diseases, and obesity among others. The company’s research emphasis can be observed in its March 2026 submission of a streamlined Phase 3 protocol for EB613, it oral PTH (1-34) tablet, to the U.S. FDA. The osteoporosis drug has been claimed to be the first oral anabolic therapy for bone rebuilding.

7. Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd., one of the top 10 oral biologics drugs players, is centered on the deployment of digital technologies for developing advanced drugs. The Japan-based company depicts a 21 times surge in operating profit over 2002 to 2024 following the strategic alliance with Roche, as per figures available on its website. To cite another collaboration, the company entered a license agreement with Rani Therapeutics in October 2025 for developing and commercializing an oral formulation based on Chugai’s rare disease antibody and the latter’s RaniPill oral development technology.

8. OPKO Health, Inc.

OPKO Health, headquartered in the U.S., provides next-generation solutions and is keen to partner with other companies to strengthen the quality of drug development and delivery. The company’s portfolio has therapeutic solutions for the treatment of various infectious disorders. In September 2023, the oral biologics drugs company inked a research collaboration agreement with Entera Bio, under which OPKO would supply certain Oxyntomodulin analogs and its proprietary long-acting GLP-2 peptide.

9. Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals caters to the needs of patients in the field of gastrointestinal care. The U.S.-headquartered company is focused on acquiring and collaborating with like-minded players for boosting its progress. An example is its USD 1.15 billion takeover of VectivBio in May 2023. The latter is a pioneer of novel treatments for severe rare gastrointestinal disorders.

10. Salix Pharmaceuticals

Salix Pharmaceuticals develops advanced solutions in the field of gastroenterology for enhancing the lives of patients. The company, with its base located in the U.S., has various therapeutic areas and is keen to conduct research activities to bring superior-quality biologics for enhanced care. To cite an example, in November 2024, Salix joined forces with its parent company Bausch Health, sharing plans to present its late-stage RED-C clinical trial program at the San Diego-based The Liver Meeting®, American Association for the Study of Liver Disease (AASLD).

Next-gen Engineering, Strategic Alliances, and Combination Therapies: The Future of Oral Biologics Drugs

In the forthcoming years, the use of advanced technologies such as next-gen engineering is likely to alter the development backdrop for oral biologics drugs. According to an article published in the journal Nature In May 2026, next-gen AI firms are depicting a surge in drug discovery investments to explore new possibilities in the field of programmable therapeutics. In addition, biologics companies are anticipated to strike strategic partnerships in the future for developing enhanced delivery platforms. Furthermore, research institutes and industry participants have been noted to explore the potential of using biologic agents in combination with other compounds/medications to enhance treatment outcomes for numerous diseases. The increasing endeavors aimed at bringing combination therapies are set to bring new opportunity windows for revenue enhancement.